2. Search Result
Search Result
Results for "

meningitis

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

4

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0712B
    Ceftriaxone sodium salt
    Maximum Cited Publications
    16 Publications Verification

    Ro 13-9904

    		 Antibiotic GSK-3 Bacterial Aurora Kinase Infection Inflammation/Immunology Cancer
    Ceftriaxone sodium salt (Ro 13-9904) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium salt is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone sodium salt is an inhibitor of Aurora B. Ceftriaxone sodium salt has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium salt can be used in the study of bacterial infections and meningitis .
    Ceftriaxone sodium salt
  • HY-B0712
    Ceftriaxone
    Maximum Cited Publications
    16 Publications Verification

    Ro 13-9904 free acid

    		 Bacterial Antibiotic GSK-3 Aurora Kinase Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis .
    Ceftriaxone
  • HY-113358
    6-keto Prostaglandin F1α
    1 Publications Verification

    		 Endogenous Metabolite Inflammation/Immunology
    6-keto Prostaglandin F1α is an endogenous metabolite present in Cerebrospinal_Fluid, Urine and Blood that can be used for the research of Meningitis, Rheumatoid Arthritis and Cardiopulmonary Resuscitation .
    6-keto Prostaglandin F1α
  • HY-N7114A
    Chloramphenicol succinate sodium
    3 Publications Verification

    		 Bacterial P2Y Receptor Succinate Dehydrogenase Drug Intermediate Infection Inflammation/Immunology
    Chloramphenicol succinate sodium is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC50 of 1.585 nM. Chloramphenicol succinate sodium serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate sodium exerts a significant inhibitory effect on colitis. Chloramphenicol succinate sodium can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .
    Chloramphenicol succinate sodium
  • HY-B0712A
    Ceftriaxone sodium hydrate
    Maximum Cited Publications
    16 Publications Verification

    Ro 13-9904 sodium hydrate

    		 Bacterial Antibiotic GSK-3 Aurora Kinase Infection Cancer
    Ceftriaxone sodium hydrate (Ro 13-9904 sodium hydrate) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium hydrate is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone sodium hydrate is an inhibitor of Aurora B. Ceftriaxone sodium hydrate has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium hydrate can be used in the study of bacterial infections and meningitis .
    Ceftriaxone sodium hydrate
  • HY-W025784
    Kalibor

    Sodium tetraphenylborate; Tetraphenylboron sodium

    		 Bacterial Infection
    Kalibor (Sodium tetraphenylborate; Tetraphenylboron sodium) is a boron-based salt and antibacterial agent. Kalibor exerts activity against Neisseria meningitidis and Neisseria gonorrhoeae. Kalibor facilitates boron uptake by Neisseria meningitidis cells. Kalibor reduces bacterial burden in a mouse model of Neisseria meningitidis bacteremia. Kalibor can be used for the research of bacterial infection, such as meningococcal bacteremia .
    Kalibor
  • HY-147110
    APX2039

    		Fungal Infection Inflammation/Immunology
    APX2039 is a brain-penetrant and orally active Gwt1 protein inhibitor. APX2039 inhibits an early step in fungal glycosylphosphatidylinositol anchor biosynthesis. APX2039 can be used for the research of cryptococcal meningitis and invasive mycosis caused by Talaromyces marneffei .
    APX2039
  • HY-P2866
    β-N-Acetylhexosaminidase, Streptococcus pneumoniae

    		Endogenous Metabolite Bacterial Infection Inflammation/Immunology
    β-N-Acetylhexosaminidase, Streptococcus pneumoniae is a cell surface virulence factor of Streptococcus pneumoniae, which contains two synergistically acting GH20 domains (with higher activity in GH20-2). β-N-Acetylhexosaminidase, Streptococcus pneumoniae specifically recognizes and hydrolyzes substrates with β(1,2) glycosidic bonds via Trp-443 and Tyr-482 residues. β-N-Acetylhexosaminidase, Streptococcus pneumoniae catalyzes the hydrolysis of β(1,2)-linked N-acetylglucosamine groups and related disaccharides, and promotes persistent colonization of bacteria in the airway by modifying host defense molecules and releasing monosaccharides for bacterial growth. β-N-Acetylhexosaminidase, Streptococcus pneumoniae can be used in studies related to Streptococcus pneumoniae infection, acute pneumonia, otitis media and meningitis .
    β-N-Acetylhexosaminidase, Streptococcus pneumoniae
  • HY-109040
    Quilseconazole

    VT-1129

    		 Fungal Cytochrome P450 Infection Inflammation/Immunology
    Quilseconazole (VT-1129) is an orally active, highly selective fungal cytochrome P450 enzyme Cyp51 inhibitor that can cross the blood-brain barrier. Quilseconazole prevents the synthesis of ergosterol, an important component of the fungal cell membrane, by inhibiting Cyp51. Quilseconazole has minimal effects on human CYP enzymes. Quilseconazole has antifungal activity and can be used in the study of cryptococcal meningitis and other diseases .
    Quilseconazole
  • HY-B0536
    Clinafloxacin

    AM-1091; CI-960; PD 127391

    		 Bacterial Antibiotic Infection
    Clinafloxacin (AM 1091) is a potent and broad-spectrum fluoroquinolone antibiotic, has inhibitory activity against gram-positive, gram-negative bacterias, and anaerobic pathogens in vitro . Clinafloxacin is against DNA gyrase and topoisomerase IV of?S. aureus with IC50 values of 0.92 μg/ml and 1.62 μg/ml, respectively .
    Clinafloxacin
  • HY-B0712R
    Ceftriaxone (Standard)

    Ro 13-9904 free acid (Standard)

    		 Reference Standards Bacterial Antibiotic GSK-3 Aurora Kinase Infection Inflammation/Immunology Cancer
    Ceftriaxone (Standard) is the analytical standard of Ceftriaxone. This product is intended for research and analytical applications. Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis[1][2][3][4][5][6][7].
    Ceftriaxone (Standard)
  • HY-B0536A
    Clinafloxacin hydrochloride

    AM 1091 hydrochloride; CI 960 hydrochloride; PD127391 hydrochloride

    		 Bacterial Antibiotic Infection
    Clinafloxacin hydrochloride (AM 1091 hydrochloride) is a potent and broad-spectrum fluoroquinolone antibiotic, has inhibitory activity against gram-positive, gram-negative bacterias, and anaerobic pathogens in vitro . Clinafloxacin hydrochloride is against DNA gyrase and topoisomerase IV of S. aureus with IC50 values of 0.92 µg/ml and 1.62 µg/ml, respectively .
    Clinafloxacin hydrochloride
  • HY-174814
    Jun15716

    		Enterovirus Infection
    Jun15716 is an Enterovirus (EVs) 2C protein (EVs 2C) inhibitor with Kis of 15.9, 44.2 and 17.8 μM for EV-D68, EV-A71 and CVB3, respectively. Jun15716 has a potent antiviral activity against EV-D68 US/MO/14-18947 and CVB3 Nancy cells (EC50s of 1.0 and 0.7 μM, respectively). Jun15716 can be used for viral infections research, such as meningitis, hand, foot and mouth disease (HFMD) and viral myocarditis .
    Jun15716
  • HY-174815
    Jun15799

    		Enterovirus Infection
    Jun15799 is an Enterovirus (EVs) 2C protein (EVs 2C) inhibitor with Kis of 0.8, 21.1 and 3.0 μM for EV-D68, EV-A71 and CVB3, respectively. Jun15799 has a significant antiviral activity against EV-D68 US/MO/14-18947, EV-A71 Tainan/4643/1998 and CVB3 Nancy cells (EC50s of 0.3, 11.4 and 0.3 μM, respectively). Jun15799 can be used for viral infections research, such as meningitis, hand, foot and mouth disease (HFMD) and viral myocarditis .
    Jun15799
  • HY-N7114
    Chloramphenicol succinate

    		Bacterial Drug Intermediate P2Y Receptor Succinate Dehydrogenase Infection Inflammation/Immunology
    Chloramphenicol succinate is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC50 of 1.585 nM. Chloramphenicol succinate serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate exerts a significant inhibitory effect on colitis. Chloramphenicol succinate can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .
    Chloramphenicol succinate
  • HY-B0712S1
    Ceftriaxone-13C2,d3 triethylammonium salt

    Ro 13-9904-13C2,d32 triethylammonium salt

    		 Antibiotic Aurora Kinase GSK-3 Bacterial Isotope-Labeled Compounds Infection Inflammation/Immunology Cancer
    Ceftriaxone-13C2,d3 triethylammonium salt is 13C and deuterated labeled Ceftriaxone (HY-B0712). Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 mM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis .
    Ceftriaxone-13C2,d3 triethylammonium salt
  • HY-176483
    Antifungal agent 133

    		Fungal Infection
    Antifungal agent 133 (compound D2) is an orally active antifungal agent with a MIC80 of 0.13 ug/mL against C.neoformans H99. Antifungal agent 133 can be used for study of cryptococcal meningitis .
    Antifungal agent 133
  • HY-118312
    CAY10657

    		NF-κB Inflammation/Immunology
    CAY10657 is an inhibitor for NF-κB pathway. CAY10657 downregulates expressions of proinflammatory cytokine (IL-6) and chemokine (MCP-1), and thus exhibits anti-inflammatory efficacy against meningitis induced by Streptococcus suis .
    CAY10657
  • HY-144632
    Antifungal agent 22

    		Fungal Infection
    Antifungal agent 22 (compound D16) is a potential and orally active antifungal agent for CM (cryptococcal meningitis), with an IC50 of 0.5 μg/mL. Antifungal agent 22 can penetrate the blood-brain barrier and kill the C. neoformans H99 cells by destroying the integrity of fungal cell membranes. Antifungal agent 22 shows selective anti-Cryptococcus activity with good metabolic stability and low cytotoxicity .
    Antifungal agent 22
  • HY-106422
    EDP-420

    EP-013420; S-013420

    		 Bacterial Infection Inflammation/Immunology
    EDP-420 (EP-013420; S-013420) is an orally active antibacterial agent. EDP-420 inhibits the Mycobacterium avium complex (MAC) in macrophages. EDP-420 reduces bacterial counts in a mouse model of macrolide infection. EDP-420 inhibits pneumococcal activity in a rabbit model of meningitis. EDP-420 can be used in research on inflammatory infectious diseases such as meningitis .
    EDP-420
  • HY-P10526
    CRAMP (1-39)

    		Bacterial Infection
    CRAMP (1-39) is an antimicrobial peptide. CRAMP (1-39) has shown potent bactericidal effects against multiple strains of Neisseria meningitidis in vitro. CRAMP (1-39) can be used to study drug-resistant bacterial infections .
    CRAMP (1-39)
  • HY-144643
    CYP51/HDAC-IN-1

    		Fungal HDAC Cytochrome P450 Inflammation/Immunology
    CYP51/HDAC-IN-1 is a potent, orally active CYP51/HDAC dual inhibitor. CYP51/HDAC-IN-1 inhibits important virulence factors and down-regulated resistance-associated genes. CYP51/HDAC-IN-1 exhibits potent therapeutic effects for both tropical candidiasis and cryptococcal meningitis .
    CYP51/HDAC-IN-1
  • HY-B0536R
    Clinafloxacin (Standard)

    AM-1091 (Standard); CI-960 (Standard); PD 127391 (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    Clinafloxacin (Standard) is the analytical standard of Clinafloxacin. This product is intended for research and analytical applications. Clinafloxacin (AM 1091) is a potent and broad-spectrum fluoroquinolone antibiotic, has inhibitory activity against gram-positive, gram-negative bacterias, and anaerobic pathogens in vitro . Clinafloxacin is against DNA gyrase and topoisomerase IV of S. aureus with IC50 values of 0.92 µg/ml and 1.62 µg/ml, respectively .
    Clinafloxacin (Standard)
  • HY-109040R
    Quilseconazole (Standard)

    VT-1129 (Standard)

    		 Fungal Cytochrome P450 Reference Standards Infection Neurological Disease Inflammation/Immunology
    Quilseconazole (Standard) is the analytical standard of Quilseconazole (HY-109040). This product is intended for research and analytical applications. Quilseconazole (VT-1129) is an orally active, highly selective fungal cytochrome P450 enzyme Cyp51 inhibitor that can cross the blood-brain barrier. Quilseconazole prevents the synthesis of ergosterol, an important component of the fungal cell membrane, by inhibiting Cyp51. Quilseconazole has minimal effects on human CYP enzymes. Quilseconazole has antifungal activity and can be used in the study of cryptococcal meningitis and other diseases .
    Quilseconazole (Standard)
  • HY-B0712AR
    Ceftriaxone sodium hydrate (Standard)

    Ro 13-9904 sodium hydrate (Standard)

    		 Reference Standards Bacterial Antibiotic GSK-3 Aurora Kinase Infection Cancer
    Ceftriaxone (sodium hydrate) (Standard) is the analytical standard of Ceftriaxone (sodium hydrate). This product is intended for research and analytical applications. Ceftriaxone sodium hydrate (Ro 13-9904 sodium hydrate) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium hydrate is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone sodium hydrate is an inhibitor of Aurora B. Ceftriaxone sodium hydrate has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium hydrate can be used in the study of bacterial infections and meningitis .
    Ceftriaxone sodium hydrate (Standard)
  • HY-N7114AR
    Chloramphenicol succinate sodium (Standard)

    		Reference Standards Bacterial Drug Intermediate P2Y Receptor Succinate Dehydrogenase Infection Inflammation/Immunology
    Chloramphenicol succinate sodium (Standard) is the analytical standard of Chloramphenicol succinate sodium. This product is intended for research and analytical applications. Chloramphenicol succinate sodium is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC50 of 1.585 nM. Chloramphenicol succinate sodium serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate sodium exerts a significant inhibitory effect on colitis. Chloramphenicol succinate sodium can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .
    Chloramphenicol succinate sodium (Standard)
  • HY-173428
    Antifungal agent 130

    		Fungal Infection
    Antifungal agent 130 (Compound A7) is an orally active antifungal agent. Antifungal agent 130 has good antifungal activity against Candida albicans (MIC = 0.12 ng/mL) and Cryptococcus neoformans (MIC = 0.12 ng/mL) and has excellent antivirulence effect. Antifungal agent 130 exerts its antifungal effect by disrupting the iron homeostasis of fungal cells and inducing oxidative stress damage. Antifungal agent 130 can inhibit the formation of fungal virulence factors (such as biofilm, capsule, urease and melanin). Antifungal agent 130 has good antifungal effect and can be used in the study of drug-resistant fungal infections .
    Antifungal agent 130
  • HY-179704
    Antifungal agent 141

    		Drug Derivative Fungal Infection
    Antifungal agent 141, a Phenoxazine (HY-34463) derivative, is an antifungal agent. Antifungal agent shows potent antifungal activity in Cryptococcus neoformans and Candida albicans with MIC values of 2 and 4 µg/mL. Antifungal agent 141 can be used for the research of cryptococcal meningitis .
    Antifungal agent 141
  • HY-B0368B
    D-Captopril

    		Beta-lactamase Antibiotic Bacterial Infection Inflammation/Immunology
    D-Captopril is a NDM-1 inhibitor and a competitive BlaB inhibitor, with an IC50 value of 21.8 µM against NDM-1 and a Ki of 70-100 µM against BlaB. D-Captopril synergistically reduces the minimum inhibitory concentration of Meropenem (HY-13678) against NDM-1-expressing bacteria. D-Captopril binds to BcII via its thiolate sulfur atom and carboxylate group, altering metal ion occupancy and modulating Cd 2+ binding affinity. D-Captopril can be used in the research of neonatal meningitis, sepsis and bacterial infections .
    D-Captopril

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: